MX2009008617A - Uso de antagonistas de interleucina-23 para el tratamiento de infeccion. - Google Patents

Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.

Info

Publication number
MX2009008617A
MX2009008617A MX2009008617A MX2009008617A MX2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A
Authority
MX
Mexico
Prior art keywords
antagonists
treatment
infection
infections
viral
Prior art date
Application number
MX2009008617A
Other languages
English (en)
Inventor
Robert A Kastelein
Manfred Kopf
Luigina Romani
Alissa A Chackerian
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009008617A publication Critical patent/MX2009008617A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen métodos y composiciones que comprenden antagonistas de IL-23 para el tratamiento de infecciones, tales como infecciones bacterianas, virales y fúngicas crónicas.
MX2009008617A 2007-02-12 2008-02-08 Uso de antagonistas de interleucina-23 para el tratamiento de infeccion. MX2009008617A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88947507P 2007-02-12 2007-02-12
PCT/US2008/001717 WO2008153610A2 (en) 2007-02-12 2008-02-08 Use of il-23 antagonists for treatment of infection

Publications (1)

Publication Number Publication Date
MX2009008617A true MX2009008617A (es) 2009-10-14

Family

ID=40130357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008617A MX2009008617A (es) 2007-02-12 2008-02-08 Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.

Country Status (13)

Country Link
US (2) US8586035B2 (es)
EP (1) EP2064246B1 (es)
JP (2) JP5320301B2 (es)
CN (1) CN101668775B (es)
AU (1) AU2008262544B2 (es)
BR (1) BRPI0807487A8 (es)
CA (1) CA2677835A1 (es)
CL (1) CL2008000418A1 (es)
MX (1) MX2009008617A (es)
NZ (2) NZ578955A (es)
TW (1) TWI426918B (es)
WO (1) WO2008153610A2 (es)
ZA (1) ZA200906126B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
WO2009108341A1 (en) * 2008-02-28 2009-09-03 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
US20130302343A1 (en) * 2011-01-04 2013-11-14 Charité Universitätsmedizin Berlin Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2015157561A1 (en) * 2014-04-09 2015-10-15 La Jolla Institute For Allergy And Immunology Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
SG11201701423RA (en) 2014-09-03 2017-03-30 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
CN105420238A (zh) * 2015-09-08 2016-03-23 中国农业科学院兰州兽医研究所 靶向抑制小鼠白细胞介素17A基因的序列siRNA-136
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3534910A4 (en) 2016-10-04 2020-11-25 Pop Test Oncology LLC THERAPEUTICS AND PROCEDURES
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
EP3634405A4 (en) * 2017-05-12 2021-06-09 The Regents of The University of California METHODS OF DETECTING DYSBIOSIS AND TREATING PATIENTS WITH DYSBIOSIS
CN108743603B (zh) * 2018-06-22 2020-06-30 山东省千佛山医院 利巴韦林单用或联合氟康唑的抗真菌产品及其应用
WO2020096058A1 (ja) * 2018-11-09 2020-05-14 学校法人立命館 皮脂腺調整剤
CN112500490B (zh) * 2020-10-14 2022-05-03 华南农业大学 一种抗左旋氧氟沙星抗体的F(ab)2片段及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE3262386D1 (en) 1981-06-06 1985-03-28 Pfizer Ltd Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
ATE248625T1 (de) * 1996-09-12 2003-09-15 Merck & Co Inc Fungizide kombinationstherapie
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1181366B2 (en) 1999-06-01 2013-08-21 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
HU230679B1 (en) 1999-09-09 2017-08-28 Merck Sharp & Dohme Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
ES2307618T3 (es) 2000-05-10 2008-12-01 Schering Corporation Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados.
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1418936A2 (en) * 2001-05-09 2004-05-19 Alk-Abell A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
KR101053412B1 (ko) * 2002-10-30 2011-08-01 제넨테크, 인크. Ｉｌ―１７ 생성의 억제
US7282204B2 (en) * 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
CA2525184C (en) * 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
SI2784084T2 (sl) * 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
EP1901768B1 (en) * 2004-02-17 2011-11-16 Schering Corporation Methods of modulating il-23 activity; related reagents
US20060193821A1 (en) 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
GB0507561D0 (en) 2005-04-14 2005-05-18 Trinity College Dublin Modulation of an immune response by filamentous haemagglutinin
HUE042561T2 (hu) * 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
DK1937721T3 (da) * 2005-08-25 2010-10-18 Lilly Co Eli Anti-IL-23 antistoffer
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2008021156A2 (en) 2006-08-11 2008-02-21 Schering Corporation Antibodies to il-17a
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
KR101520110B1 (ko) 2007-02-23 2015-05-18 머크 샤프 앤드 돔 코포레이션 가공된 항-ＩＬ-23ｐ19 항체
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
US20110158992A1 (en) 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies

Also Published As

Publication number Publication date
EP2064246B1 (en) 2013-05-22
WO2008153610A2 (en) 2008-12-18
BRPI0807487A2 (pt) 2015-09-01
JP2013014624A (ja) 2013-01-24
JP2010518087A (ja) 2010-05-27
US8586035B2 (en) 2013-11-19
EP2064246A2 (en) 2009-06-03
CA2677835A1 (en) 2008-12-18
CL2008000418A1 (es) 2008-11-14
NZ599827A (en) 2013-11-29
TWI426918B (zh) 2014-02-21
TW200902062A (en) 2009-01-16
US20140147442A1 (en) 2014-05-29
CN101668775B (zh) 2014-05-07
AU2008262544A1 (en) 2008-12-18
US20100291084A1 (en) 2010-11-18
JP5320301B2 (ja) 2013-10-23
BRPI0807487A8 (pt) 2016-02-10
NZ578955A (en) 2012-06-29
CN101668775A (zh) 2010-03-10
ZA200906126B (en) 2010-06-30
AU2008262544B2 (en) 2014-01-16
WO2008153610A3 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
WO2008115281A3 (en) Compounds for treating viral infections
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
MY181898A (en) Heterocyclic compounds and uses thereof
EP1868628A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING POXVIRUS INFECTIONS
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
WO2012076293A3 (de) Zubereitungen enthaltend polysiloxane mit stickstoffhaltigen gruppen
WO2009105513A8 (en) Novel compounds and methods for therapy
MX2011008920A (es) Composiciones oticas utiles para el tratamiento de infecciones del oido interno y externo en mamiferos.
WO2008127364A3 (en) Antiviral compounds and use thereof
HK1135101A1 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
MX364942B (es) Peptidos antimicrobianos.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
AU2015352440B2 (en) Compounds
WO2010032011A3 (en) Anti-fungal therapy
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
MX2009009743A (es) Polvos para reconstitucion.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
CL2011002967A1 (es) Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales.
MX2012004282A (es) Composiciones farmaceuticas.

Legal Events

Date Code Title Description
HH Correction or change in general
HC Change of company name or juridical status

Owner name: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC

FG Grant or registration